IPH5201 + durvalumab + standard chemotherapy

Drug identity checked against registry records

Also recorded as Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy; Durvalumab; MEDI4736, IMFINZI; Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy; Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607Innate PharmaPhase 2Recruiting2027-06Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.